

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT8365135

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT	
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT	
<b>CONVEYING PARTY DATA</b>		
	<b>Name</b>	<b>Execution Date</b>
	KBP BIOSCIENCES PTE. LTD.	11/20/2023
<b>RECEIVING PARTY DATA</b>		
<b>Name:</b>	NOVO NORDISK A/S	
<b>Street Address:</b>	NOVO ALLE 1	
<b>City:</b>	BAGSVÆRD	
<b>State/Country:</b>	DENMARK	
<b>Postal Code:</b>	2880	
<b>PROPERTY NUMBERS Total: 3</b>		
	<b>Property Type</b>	<b>Number</b>
	Application Number:	13817462
	Application Number:	14591081
	Application Number:	14653933
<b>CORRESPONDENCE DATA</b>		
<b>Fax Number:</b>	(404)815-6555	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
<b>Phone:</b>	404-745-2584	
<b>Email:</b>	mweller@kilpatricktownsend.com	
<b>Correspondent Name:</b>	KILPATRICK TOWNSEND & STOCKTON LLP	
<b>Address Line 1:</b>	SUITE 2800	
<b>Address Line 2:</b>	1100 PEACHTREE STREET NE	
<b>Address Line 4:</b>	ATLANTA, GEORGIA 30309	
<b>ATTORNEY DOCKET NUMBER:</b>	866419, 928852, 948155	
<b>NAME OF SUBMITTER:</b>	MADDIE M. WELLER	
<b>SIGNATURE:</b>	/Maddie M. Weller/	
<b>DATE SIGNED:</b>	01/05/2024	
<b>Total Attachments: 8</b>		
source=2 - Novo - KBP - Intellectual Property Assignment Agreement#page1.tif		
source=2 - Novo - KBP - Intellectual Property Assignment Agreement#page2.tif		
source=2 - Novo - KBP - Intellectual Property Assignment Agreement#page3.tif		

source=2 - Novo - KBP - Intellectual Property Assignment Agreement#page4.tif  
source=2 - Novo - KBP - Intellectual Property Assignment Agreement#page5.tif  
source=2 - Novo - KBP - Intellectual Property Assignment Agreement#page6.tif  
source=2 - Novo - KBP - Intellectual Property Assignment Agreement#page7.tif  
source=2 - Novo - KBP - Intellectual Property Assignment Agreement#page8.tif

## INTELLECTUAL PROPERTY ASSIGNMENT AGREEMENT

This Intellectual Property Assignment Agreement (“**IP Assignment Agreement**”) is made as of November 29, 2023 (the “**Effective Date**”), by and between KBP Biosciences Pte. Ltd., a Singapore private limited company (“**Assignor**”), and Novo Nordisk A/S, a Danish *Aktieselskab* (“**Assignee**”).

WHEREAS, Assignor and Assignee entered into that certain Asset Purchase Agreement dated October 11, 2023, as may be amended from time to time (the “**Asset Purchase Agreement**”); and

WHEREAS, Assignee is desirous of acquiring, in connection with the transactions contemplated by the Asset Purchase Agreement, the entire right, title and interest in and to the assets set forth in Section 2 of this IP Assignment Agreement.

NOW, THEREFORE, subject to the terms and conditions set forth in the Asset Purchase Agreement and in consideration of the premises and other good and valuable consideration as set forth in the Asset Purchase Agreement, the receipt and sufficiency of which are hereby acknowledged, Assignor and Assignee hereby agree as follows:

1. Definitions. Capitalized terms used but not otherwise defined herein shall have the meaning set forth in the Asset Purchase Agreement. Whenever used in this Agreement, the terms “include,” “includes” and “including” mean “include, without limitation,” “includes, without limitation” and “including, without limitation,” respectively.

2. Assignment. Assignor hereby sells, assigns, transfers and sets over unto Assignee, its successors, legal representatives and assigns, Assignor’s entire right, title and interest in and to all Owned Intellectual Property, effective as of the date hereof, including:

(a) all Patent Rights owned by Assignor, or that claim priority thereto, that (i) relate to the Product Business, (ii) disclose, claim or otherwise cover any Compound or Product, including the composition of matter, manufacture, formulation or method of use thereof, or (iii) are necessary or useful for (as of the Closing Date), used in prior to the Closing Date, or contemplated as of the Closing Date for use in, the research, development, manufacture, commercialization or other Exploitation of any Compound or Product, including the patents and patent applications listed in Schedule A appended hereto and all inventions disclosed therein, any and all patent applications that claim priority to or the benefit of any of the foregoing, any and all patents granted on any of the foregoing, and any and all reissues, reexaminations, supplemental examinations, renewals, and extensions of any of the foregoing;

(b) all Know-How owned by Assignor that is necessary or useful for (as of the Closing Date), the research, development, manufacture, commercialization or other Exploitation of any Compound or Product; and

(c) all rights to collect royalties and proceeds in connection with any of the foregoing, and to sue and bring other claims for past, present and future infringement,

misappropriation, unauthorized use or disclosure of or other violation of any of the foregoing, and to recover damages in connection therewith.

3. Authorization. Assignor hereby authorizes and requests the United States Patent and Trademark Office, the United States Copyright Office, and the authorities of any other applicable jurisdictions whose duty is to issue patents, trademarks, copyrights, or other evidence or forms of intellectual or industrial property protection on applications as aforesaid, to respectively issue the same to the Assignee and to respectively record the Assignee as owner of the Owned Intellectual Property, as assignee of the entire right, title and interest in, to and under the same, for the sole use and enjoyment of the Assignee and its successors, legal representatives and assigns.

4. Further Assurances. Assignor shall provide Assignee with all such assistance that Assignee may reasonably request for the full utilization of the rights granted in Section 2 above, including making or executing (or causing Assignor's current or former employees or contractors to make or execute), as applicable, all filings, applications and any further assignments or other documents or instruments, signing all lawful papers, and making all rightful oaths necessary or desirable to carry out the purposes or intent of this IP Assignment Agreement and to aid the Assignee and its successors, legal representatives and assigns to obtain and enforce proper protection for the Owned Intellectual Property in any jurisdiction and to record the Assignee as owner of the Owned Intellectual Property. Assignor's reasonable costs and expenses incurred in connection with such assistance to Assignee shall be borne by Assignee.

5. General.

(a) Governing Law. This IP Assignment Agreement (and any Claim or controversy arising out of or relating to this IP Assignment Agreement) shall be governed by and construed in accordance with the Laws of the State of New York, without giving effect to any choice or conflict of law provision or rule that would cause the application of the Laws of any jurisdiction other than the State of New York. The Assignor and Assignee irrevocably submit to the exclusive jurisdiction of (i) the Supreme Court of the State of New York, New York County and (ii) the United States District Court for the Southern District of New York for the purposes of any Claims arising out of this IP Assignment Agreement. Each of Assignor and Assignee agrees to commence any Claim relating hereto in the United States District Court for the Southern District of New York or if such Claim may not be brought in such court for jurisdictional reasons, in the Supreme Court of the State of New York, New York County. Each of Assignor and Assignee further agrees that service of any process, summons, notice or document by registered mail to such party's respective address set forth in Section 12.14 of the Asset Purchase Agreement shall be effective service of process for any Claim hereunder in New York with respect to any matters to which it has submitted to jurisdiction in this Section 5(a) any Claim arising out of this IP Assignment Agreement in the courts described above, and hereby further irrevocably and unconditionally waives, and shall not assert by way of motion, defense, or otherwise, in any Claim hereunder, any Claim that it is not subject personally to the jurisdiction of the courts described above, that its property is exempt or immune from attachment or execution, that the Claim is brought in an inconvenient forum, that the venue of the Claim is improper, or that this IP Assignment Agreement may not be enforced in or by any of the above-named courts. EACH OF ASSIGNOR AND ASSIGNEE IRREVOCABLY AND UNCONDITIONALLY WAIVES ANY

RIGHT TO TRIAL BY JURY WITH RESPECT TO ANY ACTION RELATING TO OR ARISING OUT OF ANY CLAIM CONTEMPLATED HEREIN.

(b) Counterparts. Each of Assignor and Assignee may execute this IP Assignment Agreement in one or more counterparts, each of which will be deemed an original and all of which, when taken together, will be deemed to constitute one and the same agreement. Any signature page hereto delivered by e-mail (including in portable document format (PDF)) shall be binding to the same extent as an original signature page, with regard to any agreement subject to the terms hereof or any amendment thereto and may be used in lieu of the original signatures for all purposes. Any party that delivers such a signature page agrees to later deliver an original counterpart to any party that requests it.

(c) Entire Agreement. This IP Assignment Agreement, the Asset Purchase Agreement, and the agreements and documents contemplated thereunder, including the Ancillary Agreements, contain the entire agreement of the Assignor and Assignee with respect to the Transactions, superseding all negotiations, prior discussions and preliminary agreements made prior to the date hereof. This IP Assignment Agreement may not be amended, supplemented or otherwise modified except by an instrument in writing signed by both Assignor and Assignee.

(d) Binding Agreement. This IP Assignment Agreement shall be binding upon and shall inure to the benefit of the parties hereto and their respective successors and permitted assigns. Nothing in this IP Assignment Agreement, express or implied, is intended to or shall be construed to supersede, modify, replace, amend, change, rescind, waive, exceed, enlarge, expand or limit in any way the terms of the Asset Purchase Agreement. To the extent that any provision of this IP Assignment Agreement conflicts or is inconsistent with the terms of the Asset Purchase Agreement, the Asset Purchase Agreement shall govern. This This IP Assignment Agreement is only intended to effect the transfer of the Owned Intellectual Property pursuant to the Asset Purchase Agreement and shall be governed entirely in accordance with the terms and conditions of the Asset Purchase Agreement.

[Signature page follows.]

IN WITNESS WHEREOF, Assignor has caused this Intellectual Property Assignment Agreement to be executed by its duly authorized representative effective as of the date first above written.

**FOR ASSIGNOR:**

**KBP Biosciences Pte. Ltd.**

By: 

Name: Zhenhua Huang

Title: Director

On this 20 day of NOV, 2023, there appeared before me ZHENHUA, HUANG, personally known to me, who acknowledged that he/~~she~~ signed the foregoing Intellectual Property Assignment Agreement as his/~~her~~ voluntary act and deed on behalf and with full authority of KBP Biosciences Pte. Ltd.



Notary Public



**RECEIVED BY ASSIGNEE:**

**Novo Nordisk, A/S**

By: \_\_\_\_\_

Name: \_\_\_\_\_

Title: \_\_\_\_\_

On this \_\_\_\_\_ day of \_\_\_\_\_, 2023, there appeared before me \_\_\_\_\_, personally known to me, who acknowledged that he/she signed the foregoing Intellectual Property Assignment Agreement as his/her voluntary act and deed on behalf and with full authority of Novo Nordisk, A/S.

Notary Public

[Signature page to Intellectual Property Assignment Agreement]

IN WITNESS WHEREOF, Assignor has caused this Intellectual Property Assignment Agreement to be executed by its duly authorized representative effective as of the date first above written.

**FOR ASSIGNOR:**

**KBP Biosciences Pte. Ltd.**

By: \_\_\_\_\_  
Name: Zhenhua Huang  
Title: Director


On this \_\_\_\_ day of \_\_\_, 2023, there appeared before me \_\_\_\_\_, personally known to me, who acknowledged that he/she signed the foregoing Intellectual Property Assignment Agreement as his/her voluntary act and deed on behalf and with full authority of KBP Biosciences Pte. Ltd.

\_\_\_\_\_  
Notary Public

**RECEIVED BY ASSIGNEE:**

**Novo Nordisk A/S**

By: \_\_\_\_\_  
Name: Karsten Munk Knudsen  
Title: Executive Vice President and Chief Financial Officer

DocuSigned by:  
  
C0FDB8F1DF6A41A...

On this \_\_\_\_ day of \_\_\_, 2023, there appeared before me \_\_\_\_\_, personally known to me, who acknowledged that he/she signed the foregoing Intellectual Property Assignment Agreement as his/her voluntary act and deed on behalf and with full authority of Novo Nordisk A/S.

\_\_\_\_\_  
Notary Public

[Signature page to Intellectual Property Assignment Agreement]

**PATENT**  
**REEL: 066031 FRAME: 0210**

### Schedule A

Patent Type	Jurisdiction	Application Number	Application Date	Patent Expiration Date	Status	Title
Compound of KBP-5074	China	CN201010256529.1	8/18/2010	N/A	expired	Fused Ring Compound For Use As Mineralocorticoid Receptor Antagonist
	China	CN201010558523.X	11/18/2010	N/A	expired	
	China	CN201110109741.X	4/15/2011	N/A	expired	
	PCT	PCT/CN2011/001379	8/18/2011	N/A	national phase	
	Europe	EP11817649.4 34(AT/BE/BG/CH/LI/ CZ/DE/DK/ES/FI/FR/ GB/GR/HR/HU/IE/IS/ IT/LT/LU/LV/MC/NL /NO/PL/PT/RO/SE/SI/ SK/TR/CY/EE/RS)	8/18/2011	8/18/2031	issued	
	China	ZL201180039955.2	8/18/2011	8/18/2031	issued	
	Hong Kong	HK13112927.8	8/18/2011	8/18/2031	issued	
	Macao	MO/J/001960	8/18/2011	8/18/2031	issued	
	USA	US13/817,462	8/18/2011	8/18/2031	issued	
	USA	US14/591,081	1/7/2015	8/18/2031	issued	
	Canada	CA2,808,678	8/18/2011	8/18/2031	issued	
Polymorph of KBP-5074	Japan	JP2013-524336	8/18/2011	8/18/2031	issued	
	China	201210563636.8	12/22/2012	N/A	expired	Crystal Form Of Compound Used As Mineralocorticoid Receptor Antagonist And Preparation Method Therefor
	PCT	PCT/CN2013/090252	12/23/2013	N/A	national phase	
	Europe	EP13864994.2 5(GB/FR/DE/IT/ES)	12/23/2013	12/23/2033	issued	
	Europe	EP21194531.6 Division	12/23/2013	/	pending	
	China	ZL201380066871.7	12/23/2013	12/23/2033	issued	
	Hong Kong	HK16105012.5	12/23/2013	12/23/2033	issued	
	Hong Kong	HK16100440.8	12/23/2013	12/23/2033	issued	
	Hong Kong	HK42022052378.1 Division	12/23/2013	/	pending	
	USA	US14/653,933	12/23/2013	12/23/2033	issued	
	Japan	JP2020-073415	12/23/2013	12/23/2033	issued	
	Japan	JP2021-179425	12/23/2013	/	pending	
	Mexico	MX/A/2015/008193	12/23/2013	12/23/2033	issued	
	Singapore	SG11201504928X	12/23/2013	12/23/2033	issued	
	New Zealand	NZ709361	12/23/2013	12/23/2033	issued	
	Israel	IL239581	12/23/2013	12/23/2033	issued	
	Australia	AU2013362400	12/23/2013	12/23/2033	issued	
	Canada	CA2895968	12/23/2013	12/23/2033	issued	
	South Africa	ZA2015/04485	12/23/2013	12/23/2033	issued	
	Brazil	BR112015014839-5	12/23/2013	12/23/2033	issued	
	Korea	KR10-2015-7019924	12/23/2013	12/23/2033	issued	
	India	IN202348003124	12/23/2013	/	pending	
	Russia	RU2015130222	12/23/2013	12/23/2033	issued	
Dosage of KBP-5074	China	CN201610849142.4	9/24/2016	N/A	expired	Pharmaceutical Composition Comprising Mineralocorticoid Receptor Antagonist and Use Thereof
	PCT	PCT/CN2017/102969	9/22/2017	N/A	national phase	
	Europe	EP17852425.2	9/22/2017	/	pending	
	China	ZL201780006183.X	9/22/2017	9/22/2037	issued	
	Hong Kong	HK19100983.8(CN)	9/22/2017	9/22/2037	issued	
	Hong Kong	HK19127895.1(EP)	9/22/2017	/	pending	
	Macao	MO/J/005434	9/22/2017	9/22/2037	issued	
	Taiwan	TW106132846	9/25/2017	9/25/2037	issued	
	Taiwan	TW109132042	9/25/2017	9/25/2037	issued	
	USA	US16/068,432	9/22/2017	/	issued	



Patent Type	Jurisdiction	Application Number	Application Date	Patent Expiration Date	Status	Title
	USA	US18/372,968	9/22/2017	/	pending	
	Singapore	SG11201902469X	9/22/2017	9/22/2037	issued	
	Australia	AU2017329549	9/22/2017	9/22/2037	issued	
	New Zealand	NZ751901	9/22/2017	9/22/2037	issued	
	Russia	RU2019110341	9/22/2017	9/22/2037	issued	
	Russia	RU2020120876	9/22/2017	9/22/2037	issued	
	Eurasian	EA201990668	9/22/2017	9/22/2037	issued	
	Israel	IL265560	9/22/2017	9/22/2037	issued	
	Canada	CA3,037,588	9/22/2017	9/22/2037	issued	
	South Africa	ZA2019/01740	9/22/2017	9/22/2037	issued	
	Colombia	CO2019003808	9/22/2017	9/22/2037	issued	
	Indonesia	ID-P00201902654	9/22/2017	9/22/2037	issued	
	Mexico	MX/A/2019/003339	9/22/2017	9/22/2037	issued	
	Japan	JP2019-516210	9/22/2017	9/22/2037	issued	
	India	IN201947015188	9/22/2017	9/22/2037	issued	
	Brazil	BR112019005214-3	9/22/2017	/	pending	
	Korea	KR10-2019-7009917	9/22/2017	9/22/2037	issued	
	Peru	PE2019000668	9/22/2017	/	pending	
	Chile	CL2019000753	9/22/2017	/	pending	
	Malaysia	MY-PI2019001497	9/22/2017	9/22/2037	issued	
	Thailand	TH1901001650	9/22/2017	/	pending	
	Vietnam	VN1-2019-01277	9/22/2017	/	pending	
	Morocco	MA45202	9/22/2017	9/22/2037	issued	
	Saudi Arabia	SA519401354	9/22/2017	9/22/2037	issued	
	Tunisia	TN2019/0063	9/22/2017	/	pending	
	Philippines	PH1-2019-500516	9/22/2017	9/22/2037	issued	
	Ukraine	UA-A201904176	9/22/2017	9/22/2037	issued	
	Ecuador	EC-SENADI-2019-27578	9/22/2017	/	pending	
	Honduras	HN2019000793	9/22/2017	/	pending	
	Guatemala	GT-A2019-000054	9/22/2017	/	pending	
	Cuba	CU2019000023A	9/22/2017	9/22/2037	issued	
	Dominican	DO-P2019-0072	9/22/2017	/	pending	
	Panama	PA92577-01	9/22/2017	9/22/2037	issued	
	Costa Rica	CR2019-000203	9/22/2017	/	pending	
Process of KBP-5074	China	CN201910155700.0	3/1/2019	N/A	expired	Method for Preparing Tricyclic Compound, and Intermediate Thereof
	China	CN201910187667.X	3/13/2019	N/A	expired	
	PCT	PCT/CN2020/077413	3/2/2020	N/A	national phase	
	China	CN202080018246.5	3/2/2020	/	pending	
	Hong Kong	HK62022055761.0-CN	3/2/2020	/	pending	
	Hong Kong	HK62022047570.6-EP	3/2/2020	/	pending	
	Taiwan	TW109106789	3/2/2020	3/2/2040	issued	
	Europe	EP20765627.3	3/2/2020	/	pending	
	USA	US17/435,181	3/2/2020	/	pending	
	Singapore	SG11202109564U	3/2/2020	3/2/2040	issued	
	New Zealand	NZ779681	3/2/2020	/	pending	
	Israel	IL286015	3/2/2020	/	pending	
	Australia	AU2020230627	3/2/2020	3/2/2040	issued	
	Russia	RU2021128216	3/2/2020	3/2/2040	issued	
	Canada	CA3,132,075	3/2/2020	/	pending	
	South Africa	ZA2021/06376	3/2/2020	3/2/2040	issued	
	Chile	CL2021002287	3/2/2020	/	pending	
	Indonesia	ID-P00202108221	3/2/2020	3/2/2040	issued	

Patent Type	Jurisdiction	Application Number	Application Date	Patent Expiration Date	Status	Title
	Mexico	MX/A/2021/010511	3/2/2020	/	pending	
	Colombia	CO20210012061	3/2/2020	/	pending	
	Japan	JP2021-551807	3/2/2020	/	issued	
	Brazil	BR112021017276-9	3/2/2020	/	pending	
	Korea	KR10-2021-7031105	3/2/2020	/	pending	
	India	IN202147043840	3/2/2020	/	pending	
	Philippines	PH1-2021-552095	3/2/2020	/	pending	
	Vietnam	VN1-2021-05744	3/2/2020	/	pending	
	Peru	PE1428-2021	3/2/2020	/	pending	
	Malaysia	MY-PI2021004999	3/2/2020	/	pending	
	Thailand	TH2101005157	3/2/2020	/	pending	
	Ukraine	UA-A202105530	3/2/2020	/	pending	
	Cambodia	KH/P/2021/00048	3/2/2020	/	pending	
Preparation of KBP5074	China	CN202210421411.2	2022/04/21	N/A	withdrawn	A pharmaceutical composition containing a mineralocorticoid receptor antagonist and preparation method thereof
Combination Therapy Involving KBP5074	China	CN202210469066.X	2022/04/29	N/A	withdrawn	Pharmaceutical combination of mineralocorticoid receptor antagonist and SGLT2 inhibitor
Compound of KBP-3990	China	CN201010256527.2	2010/08/18	N/A	expired	Dihydropyrazole compounds
	China	CN201010549656.0	2010/11/12	N/A	expired	
	China	CN201110080789.2	2011/03/23	N/A	expired	
	PCT	PCT/CN2011/001378	2011/08/18	N/A	national phase	
	China	ZL201180031781.5	2011/08/18	2031/08/18	issued	
Compound of KBP-5139	China	CN201110065758.X	2011/03/18	N/A	expired	Dihydropyrazole compounds containing heterocycles
	China	ZL201210070686.2	2012/03/16	2032/03/16	issued	
Compound of KBP-5150	China	CN201110065760.7	2011/03/18	N/A	expired	Spiro-containing dihydropyrazole compounds
	PCT	PCT/CN2012/000327	2012/03/16	N/A	national phase	
	China	ZL201280011160.5	2012/03/16	2032/03/16	issued	